<DOC>
	<DOCNO>NCT00500305</DOCNO>
	<brief_summary>A patent ductus arteriosus ( PDA ) associate increased morbidity premature infant . Standard indomethacin treatment associate intestinal renal morbidity . B-type natriuretic peptide elevate significant PDAs . This study determine whether BNP guide therapy could reduce dos indomethacin .</brief_summary>
	<brief_title>The Use B-Type Natriuretic Peptide ( BNP ) Predict Closure Patent Ductus Arteriosus ( PDA ) Premature Infants</brief_title>
	<detailed_description />
	<mesh_term>Ductus Arteriosus , Patent</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<criteria>Infants echocardiographically confirm PDA Infants determine attend physician require PDA closure infant congenital heart disease infant creatinine value &gt; 2.0</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>4 Months</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>indomethacin therapy</keyword>
	<keyword>patent ductus arteriosus</keyword>
</DOC>